Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 6/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914164 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1DPP4DPP7 | |
| SCHEMBL8396013 | 0.84 | LMNA (0.60) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5263738 | 0.83 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5263741 | 0.83 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8391394 | 0.81 | MEN1 (0.63) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8393973 | 0.80 | MEN1 (0.65) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8393628 | 0.80 | MEN1 (0.65) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6617894 | 0.79 | KMT2A (0.54) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8396587 | 0.79 | LMNA (0.63) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8392818 | 0.77 | HTT (0.62) | MEN1KMT2AALDH1A1DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | MEN1 438/4885KMT2A 1926/4885ALDH1A1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.